Gene Therapies

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

Korean brand Dr. Reju-All's pharmacist-led approach and PDRN science captivated nearly 5,000 dermatologists, signaling a new wave in U.S. skincare.

With a fresh CAD $1M in funding, Grey Matters is set to enter the booming U.S. neuroimaging market, targeting early Alzheimer's detection.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

A novel drug candidate from Addex Therapeutics shows robust cough suppression in key preclinical studies, offering hope for a treatment without current side effects.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

A breakthrough drug for pediatric Hunter syndrome, AVLAYAH™, is now accessible via home infusion through an exclusive Orsini and Denali partnership.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

Nested Therapeutics' NST-628 reports a 38% response rate in advanced melanoma, offering new hope with a novel, brain-penetrating cancer-fighting agent.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A new FDA-approved powder form of a common blood pressure drug aims to solve a daily struggle for the elderly, children, and tube-fed patients.